Biotie, the specialised drug development company focused on products for neurodegenerative and psychiatric disorders, has announced that its partner Lundbeck has launched Selincro in Spain.
Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (>60 g/day for men, >40 g/day for women) without physical withdrawal symptoms and who do not require immediate detoxification.
Biotie, the specialised drug development company focused on products for neurodegenerative and psychiatric disorders, has announced that its partner Lundbeck has launched Selincro in Spain.
Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (>60 g/day for men, >40 g/day for women) without physical withdrawal symptoms and who do not require immediate detoxification.
According to the terms of the licence agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment of €2 million related to the market entry. Lundbeck will continue the rollout of Selincro in additional European markets during 2014.
